GLP-1 agonists, like semaglutide and tirzepatide, target the gut-brain axis, offering significant benefits in obesity management by mimicking gut hormones. Imaging advancements, including CAC scoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results